$491.75
0.180.04%
Pre-Market: Jul 19, 5:21 PM EDT
15 minutes delayed
Comments
Loading...
Vertex Pharmaceuticals
VRTXNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Vertex Pharmaceuticals (NASDAQ:VRTX) Stock, Analyst Ratings, Price Targets, Forecasts
Vertex Pharmaceuticals Inc has a consensus price target of $453.08 based on the ratings of 29 analysts. The high is $559 issued by Goldman Sachs on January 31, 2024. The low is $325 issued by Baird on May 2, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Morgan Stanley, and Redburn Atlantic on July 19, 2024, July 11, 2024, and June 27, 2024, respectively. With an average price target of $500 between HC Wainwright & Co., Morgan Stanley, and Redburn Atlantic, there's an implied 1.68% upside for Vertex Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Morgan Stanley
Redburn Atlantic
Wells Fargo
Argus Research
1calculated from analyst ratings
Analyst Ratings for Vertex Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/19/2024 | Buy Now | 1.68% | HC Wainwright & Co. | Andrew Fein | $462 → $500 | Maintains | Buy | Get Alert |
| 07/11/2024 | Buy Now | -7.47% | Morgan Stanley | Matthew Harrison | $402 → $455 | Maintains | Equal-Weight | Get Alert |
| 06/27/2024 | Buy Now | 10.83% | Redburn Atlantic | Steve Chesney | → $545 | Initiates | → Buy | Get Alert |
| 06/24/2024 | Buy Now | 12.86% | Wells Fargo | Mohit Bansal | $540 → $555 | Maintains | Overweight | Get Alert |
| 06/17/2024 | Buy Now | 11.85% | Argus Research | Jasper Hellweg | $465 → $550 | Maintains | Buy | Get Alert |
| 06/11/2024 | Buy Now | -14.39% | RBC Capital | Brian Abrahams | $424 → $421 | Maintains | Sector Perform | Get Alert |
| 06/04/2024 | Buy Now | -13.78% | RBC Capital | Brian Abrahams | $424 → $424 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 05/31/2024 | Buy Now | 1.68% | BMO Capital | Evan Seigerman | $480 → $500 | Maintains | Outperform | Get Alert |
| 05/07/2024 | Buy Now | -6.05% | HC Wainwright & Co. | Andrew Fein | → $462 | Reiterates | Buy → Buy | Get Alert |
| 05/07/2024 | Buy Now | -13.78% | RBC Capital | Brian Abrahams | $417 → $424 | Maintains | Sector Perform | Get Alert |
| 05/07/2024 | Buy Now | -7.27% | Piper Sandler | Christopher Raymond | $450 → $456 | Maintains | Overweight | Get Alert |
| 05/07/2024 | Buy Now | — | Needham | Joseph Stringer | — | Reiterates | → Hold | Get Alert |
| 04/18/2024 | Buy Now | -8.49% | Guggenheim | Debjit Chattopadhyay | $445 → $450 | Maintains | Buy | Get Alert |
| 04/17/2024 | Buy Now | -5.24% | UBS | Colin Bristow | $498 → $466 | Maintains | Buy | Get Alert |
| 04/15/2024 | Buy Now | 1.68% | Oppenheimer | Hartaj Singh | → $500 | Maintains | Outperform | Get Alert |
| 04/12/2024 | Buy Now | -24.56% | Canaccord Genuity | Whitney Ijem | $371 → $371 | Maintains | Sell | Get Alert |
| 04/11/2024 | Buy Now | -6.05% | HC Wainwright & Co. | Andrew Fein | $457 → $462 | Maintains | Buy | Get Alert |
| 04/11/2024 | Buy Now | -10.93% | Evercore ISI Group | Liisa Bayko | → $438 | Upgrade | In-Line → Outperform | Get Alert |
| 02/20/2024 | Buy Now | -10.52% | Cantor Fitzgerald | Olivia Brayer | → $440 | Reiterates | Overweight → Overweight | Get Alert |
| 02/15/2024 | Buy Now | — | Wolfe Research | Andy Chen | — | Initiates | → Outperform | Get Alert |
| 02/06/2024 | Buy Now | -10.52% | Cantor Fitzgerald | Olivia Brayer | → $440 | Reiterates | Overweight → Overweight | Get Alert |
| 02/06/2024 | Buy Now | -8.49% | JP Morgan | Jessica Fye | $438 → $450 | Maintains | Overweight | Get Alert |
| 02/06/2024 | Buy Now | 9.81% | Wells Fargo | Mohit Bansal | $500 → $540 | Maintains | Overweight | Get Alert |
| 02/06/2024 | Buy Now | -14.59% | RBC Capital | Brian Abrahams | $397 → $420 | Maintains | Sector Perform | Get Alert |
| 02/06/2024 | Buy Now | -4.02% | Barclays | Gena Wang | $446 → $472 | Maintains | Overweight | Get Alert |
| 02/06/2024 | Buy Now | -10.93% | Evercore ISI Group | Liisa Bayko | $436 → $438 | Downgrade | Outperform → In-Line | Get Alert |
| 02/06/2024 | Buy Now | -7.07% | HC Wainwright & Co. | Andrew Fein | $397 → $457 | Maintains | Buy | Get Alert |
| 02/02/2024 | Buy Now | — | Bernstein | William Pickering | — | Downgrade | Outperform → Market Perform | Get Alert |
| 02/01/2024 | Buy Now | -10.93% | JP Morgan | Jessica Fye | $390 → $438 | Maintains | Overweight | Get Alert |
| 01/31/2024 | Buy Now | 3.3% | Truist Securities | Robyn Karnauskas | $456 → $508 | Maintains | Buy | Get Alert |
| 01/31/2024 | Buy Now | 13.68% | Goldman Sachs | Salveen Richter | $442 → $559 | Maintains | Buy | Get Alert |
| 01/31/2024 | Buy Now | — | Maxim Group | Naz Rahman | — | Downgrade | Buy → Hold | Get Alert |
| 01/24/2024 | Buy Now | -10.52% | Cantor Fitzgerald | Olivia Brayer | $415 → $440 | Maintains | Overweight | Get Alert |
| 01/24/2024 | Buy Now | -22.93% | Canaccord Genuity | Whitney Ijem | $332 → $379 | Downgrade | Hold → Sell | Get Alert |
| 01/12/2024 | Buy Now | -15.61% | Cantor Fitzgerald | Olivia Brayer | → $415 | Reiterates | Overweight → Overweight | Get Alert |
| 01/09/2024 | Buy Now | -15.61% | Cantor Fitzgerald | Olivia Brayer | → $415 | Reiterates | Overweight → Overweight | Get Alert |
| 12/14/2023 | Buy Now | -22.72% | Cantor Fitzgerald | Olivia Brayer | → $380 | Reiterates | Overweight → Overweight | Get Alert |
| 12/14/2023 | Buy Now | -22.93% | RBC Capital | Brian Abrahams | $347 → $379 | Maintains | Sector Perform | Get Alert |
| 12/11/2023 | Buy Now | -15.61% | Barclays | Gena Wang | $408 → $415 | Maintains | Overweight | Get Alert |
| 12/11/2023 | Buy Now | -19.27% | HC Wainwright & Co. | Andrew Fein | $390 → $397 | Maintains | Buy | Get Alert |
| 12/05/2023 | Buy Now | -22.72% | Cantor Fitzgerald | Olivia Brayer | → $380 | Reiterates | Overweight → Overweight | Get Alert |
| 11/22/2023 | Buy Now | -24.15% | Stifel | Paul Matteis | → $373 | Reiterates | Hold → Hold | Get Alert |
| 11/16/2023 | Buy Now | -22.72% | Cantor Fitzgerald | Olivia Brayer | → $380 | Reiterates | Overweight → Overweight | Get Alert |
| 11/08/2023 | Buy Now | -25.98% | Morgan Stanley | Matthew Harrison | $359 → $364 | Maintains | Equal-Weight | Get Alert |
| 11/07/2023 | Buy Now | -29.44% | RBC Capital | Brian Abrahams | $350 → $347 | Maintains | Sector Perform | Get Alert |
| 11/07/2023 | Buy Now | -15.61% | BMO Capital | Evan Seigerman | $389 → $415 | Maintains | Outperform | Get Alert |
| 11/07/2023 | Buy Now | -22.72% | Cantor Fitzgerald | Olivia Brayer | $370 → $380 | Maintains | Overweight | Get Alert |
| 11/07/2023 | Buy Now | -24.15% | Stifel | Paul Matteis | $340 → $373 | Maintains | Hold | Get Alert |
| 11/07/2023 | Buy Now | -20.69% | HC Wainwright & Co. | Andrew Fein | $380 → $390 | Maintains | Buy | Get Alert |
| 10/17/2023 | Buy Now | -24.76% | Cantor Fitzgerald | Eric Schmidt | → $370 | Reiterates | Overweight → Overweight | Get Alert |
| 10/16/2023 | Buy Now | -24.76% | Cantor Fitzgerald | Olivia Brayer | → $370 | Reiterates | Overweight → Overweight | Get Alert |
| 10/09/2023 | Buy Now | -27% | Morgan Stanley | Matthew Harrison | $352 → $359 | Maintains | Equal-Weight | Get Alert |
| 10/04/2023 | Buy Now | -7.27% | Truist Securities | Robyn Karnauskas | → $456 | Reiterates | Buy → Buy | Get Alert |
| 09/29/2023 | Buy Now | -29.23% | RBC Capital | Brian Abrahams | $343 → $348 | Maintains | Sector Perform | Get Alert |
| 09/07/2023 | Buy Now | -24.76% | Cantor Fitzgerald | Olivia Brayer | → $370 | Reiterates | Overweight → Overweight | Get Alert |
| 08/07/2023 | Buy Now | -35.94% | Canaccord Genuity | Whitney Ijem | $312 → $315 | Maintains | Hold | Get Alert |
| 08/02/2023 | Buy Now | -24.76% | TD Cowen | Phil Nadeau | $360 → $370 | Maintains | Outperform | Get Alert |
| 08/02/2023 | Buy Now | -24.76% | Cantor Fitzgerald | Olivia Brayer | $365 → $370 | Reiterates | Overweight → Overweight | Get Alert |
| 08/02/2023 | Buy Now | -30.25% | RBC Capital | Brian Abrahams | $325 → $343 | Maintains | Sector Perform | Get Alert |
| 08/02/2023 | Buy Now | -28.42% | Morgan Stanley | Matthew Harrison | $340 → $352 | Maintains | Equal-Weight | Get Alert |
| 08/02/2023 | Buy Now | -20.89% | BMO Capital | Evan Seigerman | $385 → $389 | Maintains | Outperform | Get Alert |
| 08/02/2023 | Buy Now | -13.57% | Wells Fargo | Mohit Bansal | $410 → $425 | Maintains | Overweight | Get Alert |
| 08/02/2023 | Buy Now | -16.62% | Oppenheimer | Hartaj Singh | → $410 | Reiterates | Outperform → Outperform | Get Alert |
| 08/02/2023 | Buy Now | -20.69% | Bernstein | William Pickering | $380 → $390 | Maintains | Outperform | Get Alert |
| 08/02/2023 | Buy Now | -18.86% | Barclays | Gena Wang | $384 → $399 | Maintains | Overweight | Get Alert |
| 08/02/2023 | Buy Now | -22.72% | HC Wainwright & Co. | Andrew Fein | → $380 | Reiterates | Buy → Buy | Get Alert |
| 08/01/2023 | Buy Now | -50.18% | Evercore ISI Group | Liisa Bayko | → $245 | Maintains | Outperform | Get Alert |
| 07/28/2023 | Buy Now | -22.72% | Bernstein | William Pickering | → $380 | Maintains | Outperform | Get Alert |
| 07/24/2023 | Buy Now | -13.78% | UBS | Colin Bristow | $399 → $424 | Maintains | Buy | Get Alert |
| 07/21/2023 | Buy Now | -18.66% | B of A Securities | Ying Huang | $350 → $400 | Maintains | Buy | Get Alert |
| 06/30/2023 | Buy Now | -30.86% | Morgan Stanley | Matthew Harrison | $305 → $340 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 06/28/2023 | Buy Now | -26.79% | TD Cowen | Phil Nadeau | $350 → $360 | Maintains | Outperform | Get Alert |
| 06/26/2023 | Buy Now | -22.93% | Evercore ISI Group | Liisa Bayko | $375 → $379 | Maintains | Outperform | Get Alert |
| 06/26/2023 | Buy Now | -22.72% | HC Wainwright & Co. | Andrew Fein | → $380 | Reiterates | Buy → Buy | Get Alert |
| 06/23/2023 | Buy Now | -25.78% | Cantor Fitzgerald | Olivia Brayer | $365 → $365 | Reiterates | Overweight → Overweight | Get Alert |
| 06/22/2023 | Buy Now | -34.32% | RBC Capital | Brian Abrahams | → $323 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 06/12/2023 | Buy Now | -22.72% | HC Wainwright & Co. | Andrew Fein | → $380 | Reiterates | Buy → Buy | Get Alert |
| 06/08/2023 | Buy Now | -34.32% | RBC Capital | Brian Abrahams | $315 → $323 | Maintains | Sector Perform | Get Alert |
| 05/30/2023 | Buy Now | -25.78% | Cantor Fitzgerald | Olivia Brayer | → $365 | Reiterates | Overweight → Overweight | Get Alert |
| 05/30/2023 | Buy Now | — | William Blair | Myles Minter | — | Initiates | → Outperform | Get Alert |
| 05/04/2023 | Buy Now | -21.71% | Piper Sandler | Christopher Raymond | → $385 | Assumes | → Overweight | Get Alert |
| 05/03/2023 | Buy Now | -18.66% | Maxim Group | Jason McCarthy | $325 → $400 | Maintains | Buy | Get Alert |
| 05/03/2023 | Buy Now | -26.18% | Bernstein | William Pickering | $344 → $363 | Maintains | Outperform | Get Alert |
| 05/02/2023 | Buy Now | -18.86% | UBS | Colin Bristow | $375 → $399 | Maintains | Buy | Get Alert |
| 05/02/2023 | Buy Now | -29.84% | JP Morgan | Jessica Fye | → $345 | Maintains | Overweight | Get Alert |
| 05/02/2023 | Buy Now | -28.83% | TD Cowen | Phil Nadeau | $330 → $350 | Maintains | Outperform | Get Alert |
| 05/02/2023 | Buy Now | -21.71% | BMO Capital | Evan Seigerman | → $385 | Maintains | Outperform | Get Alert |
| 05/02/2023 | Buy Now | -7.27% | Truist Securities | Robyn Karnauskas | $341 → $456 | Maintains | Buy | Get Alert |
| 05/02/2023 | Buy Now | -35.94% | RBC Capital | Brian Abrahams | $299 → $315 | Maintains | Sector Perform | Get Alert |
| 05/02/2023 | Buy Now | -37.98% | Morgan Stanley | Matthew Harrison | $285 → $305 | Maintains | Equal-Weight | Get Alert |
| 05/02/2023 | Buy Now | -30.86% | Stifel | Paul Matteis | $300 → $340 | Maintains | Hold | Get Alert |
| 05/02/2023 | Buy Now | -21.71% | Guggenheim | Debjit Chattopadhyay | $339 → $385 | Maintains | Buy | Get Alert |
| 05/02/2023 | Buy Now | -33.91% | Baird | Brian Skorney | $280 → $325 | Maintains | Neutral | Get Alert |
| 05/02/2023 | Buy Now | -16.62% | Oppenheimer | Hartaj Singh | $350 → $410 | Maintains | Outperform | Get Alert |
| 05/02/2023 | Buy Now | -22.72% | HC Wainwright & Co. | Andrew Fein | $326 → $380 | Maintains | Buy | Get Alert |
| 05/02/2023 | Buy Now | -21.91% | Barclays | Gena Wang | $342 → $384 | Maintains | Overweight | Get Alert |
| 04/06/2023 | Buy Now | -39.2% | RBC Capital | Brian Abrahams | → $299 | Maintains | Sector Perform | Get Alert |
| 03/29/2023 | Buy Now | -28.83% | Argus Research | Jasper Hellweg | $340 → $350 | Maintains | Buy | Get Alert |
| 03/21/2023 | Buy Now | -30.05% | Bernstein | William Pickering | → $344 | Initiates | → Outperform | Get Alert |
| 02/09/2023 | Buy Now | -38.99% | Stifel | Paul Matteis | $289 → $300 | Maintains | Hold | Get Alert |
FAQ
What is the target price for Vertex Pharmaceuticals (VRTX) stock?
The latest price target for Vertex Pharmaceuticals (NASDAQ:VRTX) was reported by HC Wainwright & Co. on July 19, 2024. The analyst firm set a price target for $500.00 expecting VRTX to rise to within 12 months (a possible 1.68% upside). 69 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Vertex Pharmaceuticals (VRTX)?
The latest analyst rating for Vertex Pharmaceuticals (NASDAQ:VRTX) was provided by HC Wainwright & Co., and Vertex Pharmaceuticals maintained their buy rating.
When was the last upgrade for Vertex Pharmaceuticals (VRTX)?
The last upgrade for Vertex Pharmaceuticals Inc happened on April 11, 2024 when Evercore ISI Group raised their price target to $438. Evercore ISI Group previously had an in-line for Vertex Pharmaceuticals Inc.
When was the last downgrade for Vertex Pharmaceuticals (VRTX)?
The last downgrade for Vertex Pharmaceuticals Inc happened on February 6, 2024 when Evercore ISI Group changed their price target from $436 to $438 for Vertex Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Vertex Pharmaceuticals (VRTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vertex Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vertex Pharmaceuticals was filed on July 19, 2024 so you should expect the next rating to be made available sometime around July 19, 2025.
Is the Analyst Rating Vertex Pharmaceuticals (VRTX) correct?
While ratings are subjective and will change, the latest Vertex Pharmaceuticals (VRTX) rating was a maintained with a price target of $462.00 to $500.00. The current price Vertex Pharmaceuticals (VRTX) is trading at is $491.75, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.